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An Ex Vivo Model Employing Keloid-Derived
Cell–Seeded Collagen Sponges for Therapy
Development
Yosuke Yagi1,2,6, Eri Muroga1,6, Motoko Naitoh3, Zenzo Isogai4, Seiya Matsui1,5, Susumu Ikehara2,
Shigehiko Suzuki3, Yoshiki Miyachi1 and Atsushi Utani2
The most distinctive feature of keloid is the extreme deposition of extracellular matrix, including collagens and
proteoglycans (PGs). The focus of this study was the PG versican, which presumably defines keloid volume
because of its ability to retain large amounts of water through its component glycosaminoglycans (GAGs). The
excessive deposition of versican in keloids was examined by immunohistochemical analysis and by
upregulation of the versican gene in these lesions by real-time PCR. The latter showed that mesenchymal
cells derived from keloid lesion (KL) cells continue to exhibit above-normal versican production in culture. To
establish a model of GAG deposition in keloids, collagen sponges seeded with KL cells (KL-SPos) were
implanted in the subcutaneous space of nude mice. After 1 month, the KL-SPos were significantly heavier than
the fibroblast (Fb)-seeded sponges (Fb-SPos). This ex vivo model was subsequently used to examine an
inhibitory ability of IL-1b that was identified to reduce versican in vitro. IL-1b or chondroitinase ABC, when
injected directly, successfully reduced the weight of the KL-SPos. Thus, on the basis of the change in weight of
the seeded sponges, this ex vivo model can be used to test therapies aimed at reducing or inhibiting keloid
formation and to study the pathogenesis of this aberrant response.
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INTRODUCTION
Keloids occur spontaneously or following minor trauma,
expanding beyond the boundaries of the original wound and
causing serious functional and cosmetic problems. In people
predisposed to keloid development, normal wound-healing
processes are derailed, leading to an exuberant cellular
response that includes excessive extracellular matrix (ECM)
production and deposition (Wolfram et al., 2009).
Our group (Naitoh et al., 2005), as well as others (Smith
et al., 2008), determined that ECMs are overexpressed in
keloid tissues and cells, respectively, using microarray assays.
Recently, we demonstrated that micro-RNA-mediated mechan-
isms, namely a significant decrease in the level of miR196, was
involved in the increased collagen synthesis characteristic of
keloids (Kashiyama et al., 2012). In addition, we showed that in
these lesions, elastic fiber formation is disrupted because of the
excess amounts of the glycosaminoglycan (GAG), chondroitin
sulfate (CS), and dermatan sulfate (DS) (Ikeda et al., 2009).
Versican is a member of the CS/DS–proteoglycan (PG)
family. It is distributed in a variety of soft tissues and
participates in cell adhesion, migration, proliferation, differ-
entiation, and cartilage development (Wu et al., 2005;
Matsumoto et al., 2006).
The sulfate or carbonyl moieties that form the long GAG
side chains of versican enable it to hold large amounts
of water. As excessive PG deposition contributes significantly
to keloid volume, the elimination of these molecules
by targeted treatment would significantly contribute to
resolving the clinical problems associated with keloid devel-
opment. Currently, international clinical recommendations
on scar management, including keloids, comprise several
treatment modalities (Mustoe et al., 2002). However, among
these, triamcinolone, surgery, radiation, and combination
therapy have been shown to actually promote the recurrence
of keloids rather than permanently eliminate them (Al-Attar
et al., 2006; van de Kar et al., 2007; Butler et al., 2008). The
difficulty in developing a successful therapeutic strategy is
further complicated by the absence of an appropriate model
of keloids, a refractory disorder that is specific to humans.
The GAG deposition model of keloids developed in this
study was based upon our observation of increased versican
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transcription in primary cultured keloid cells, as determined
in promoter assays. Sponges seeded with these aberrant cells
were implanted into the subcutaneous space of nude mice
and were used to study the inhibitory effect of several
compounds. Of the cytokines and growth factors tested, only
IL-1b inhibited versican expression. Thus, this animal model
provides an invaluable approach to the development of
effective therapies aimed at reducing keloid formation, which
can then be tested in human trials. Furthermore, it can be
used to identify the in vivo components that promote ECM
formation in these abnormal tissues.
RESULTS
Versican accumulation and upregulation of the gene in keloids
In a previous study (Ikeda et al., 2009), we found that the
ECM deposited in keloids contains large amount of CS and
DS. Microarray assays analyzing these tissues showed that
versican and other PGs comprising the ECM were expressed
at higher levels than in nonlesional skin (Naitoh et al., 2005).
To confirm that versican is expressed at aberrantly high
levels in keloids, we subjected six samples of keloids (K1–K6)
to histopathological analysis. Hematoxylin–eosin staining
revealed numerous fibrillar collagenous matrices forming
a whorled pattern and a central collection of broad, compact,
hyalinized, and collagenous bundles (Figure 1a). The
presence of massive amounts of GAGs in these matrices
was evidenced by toluidine blue staining (Figure 1a). Immu-
nohistochemical analysis with anti-versican antibody demon-
strated intense versican deposition in the keloids, but not in
nonlesional skin (Figure 1a). However, there was no differ-
ence in hyaluronan accumulation (Figure 1a). These observa-
tions suggest that versican is a specific marker of keloids.
Alternative splicing produces several versican isoforms,
designated V0–V3 (Wu et al., 2005). Two major versican
transcripts, namely the V0 and V1 isoforms, were detected in
both normal human skin and in keloids by real-time PCR (RT-
PCR) analysis (data not shown). RT-PCR analysis of the three
keloid-derived RNAs and the three normal skin–derived RNAs
revealed substantially higher versican mRNA levels in keloids
than in normal skin (Figure 1b). Semiquantitative RT-PCR of
the six keloid-derived RNAs (K1–K6) and the RNAs derived
from five normal skin samples (N1–N5) showed a similar
tendency (data not shown).
Primary cultured cells derived from keloids continue to
overexpress PGs
Eight keloid cell lines (keloid lesion (KL) cells) were
established from eight individuals and eight normal fibroblast
(Fb) lines were established from another eight. Microarray
analysis of the ECM using KL and Fb cell line showed that the
former continued to overexpress ECM, and showed upregula-
tion of three PGs (versican, aggrecan, and lumican) under the
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Figure 1. Versican accumulation and upregulation in keloids. (a) Hematoxylin–eosin (HE) staining revealed the deposition of an abnormal fibrillar collagenous
matrix within the keloids. Toluidine blue (TB) staining at pH 2.5 showed metachromasia, indicative of glycosaminoglycan accumulation in the keloids.
Arrows point to the boundary of the lesion. The keloids contained large deposits of versican, but there was no increase in hyaluronan (HA) levels. Representative
images of the keloids obtained from six individuals are shown. Bar¼ mm. (b) Real-time PCR analysis of versican mRNA expression in samples of normal skin
and of keloids. Mean±SD and versican/glyceraldehyde 3-phosphate dehydrogenase ratios are shown.
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culture conditions used (Table 1); all three PGs are
upregulated in tissues (Naitoh et al., 2005).
Upregulation of versican expression in KL cells
To determine whether versican is specifically upregulated in
primary cultured KL cells, versican mRNA levels were mea-
sured. As shown by RT-PCR, the ratio of versican to
glyceraldehyde 3-phosphate dehydrogenase expression in
KL cells was 2.54±0.53-fold higher than that in Fbs (n¼5 for
both KL cells and Fbs) (Figure 2a). Furthermore, we used
luciferase reporter assays to examine the activity of the
versican promoter region, spanning 559 to þ353, in KL
cells and Fbs. As shown in Figure 2b, luciferase activity was
1.73±0.22-fold higher in KL cells. After confirming that
antibody 2B1 specifically bound to versican, we performed
dot-blot analysis, which showed that KL cells overproduce
versican protein (4.71±2.53-fold higher than Fbs; Figure 2c).
Regulation of versican expression
Hypothesizing that a decrease in versican expression would
lead to a corresponding reduction in keloid volume, we
screened various cytokines, growth factors, and signaling
pathway inhibitors. We carried out a series of studies in
which LY294002, SB202190, and PD98059 were used to
inhibit the PI3K, p38 MAPK, and ERK pathways, respectively.
The results showed that PI3K and p38 MAPK, but not ERK,
stimulated versican expression in both KL cells and Fbs
(Figure 3a).
Among the growth factors and cytokines tested. The
addition of IL-1b to Fbs and KL cells reduced versican
expression in both, by 49.6±13% and 21.2±3.3%, respec-
tively, compared with the corresponding untreated cells
(Figure 3b). These results are consistent with other studies in
which IL-1b reportedly suppressed versican expression in
gingival Fbs (Qwarnstrom et al., 1993) and arterial smooth
muscle cells (Lemire et al., 2007). Exogenous IL-1b also
suppressed relative promoter activity in Fbs and KL cells, as
evidenced by a decrease in luciferase activity of 65.8±6.9%
and 36.5±10%, respectively (Figure 3c).
We then examined whether differences in the expression
of IL-1b and IL-1 receptors by KL cells and Fbs accounted for
the differential response to IL-1b and thus for the upregulation
of versican in KL cells. ELISA assays showed that the amounts
of endogenous IL-1b protein in the conditioned medium of
both cell types were below the detectable limit (data not
shown). Furthermore, according to RT-PCR, KL cells and Fb
contain similar levels of IL-1 receptor mRNA (data not
shown). Finally, the addition of an IL-1 receptor antagonist
did not affect versican expression, although it completely
blocked IL-1b-induced versican downregulation (Figure 3d).
These results indicate that endogenous IL-1b is not involved
in versican gene regulation under these experimental condi-
tions.
Generation of an ex vivo GAG deposition model in mice
As noted above, keloid formation occurs only in humans, and
thus there is no appropriate animal model. We therefore
sought to establish an ex vivo model using the ECM-
overproducing KL cells. In a previous study, we found that
Table 1. Microarray analysis of upregulated ECM
genes in KL cells
Gene Protein mRNA KL cells /mRNA Fb1
COL10A1 Collagen a1 (X) 10.4
COL2A1 Collagen a1 (II) 10.3
ACAN Aggrecan 6.2
COL9A1 Collagen a2 (IX) 3.9
COL11A1 Collagen a1 (XI) 3.6
LUM Lumican 3.4
COL8A1 Collagen a1 (VIII) 2.8
VCAN Versican 2.5
THBS1 Thrombospondin 1 2.4
COL17A1 Collagen a1 (XVII) 2.2
COL9A3 Collagen a3 (IX) 2.1
Abbreviations: ECM, extracellular matrix; Fb, fibroblast; KL, keloid lesion.
1Determined by microarray analysis performed in the current study.
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Figure 2. Versican upregulation in cultured keloid lesion (KL) cells. (a) KL
cells and fibroblasts (Fbs) were analyzed for versican expression by real-time
PCR. Versican/glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ratios
were calculated by setting the versican mRNA expression of one Fb cell line
at 100%. The mean±SD and the versican/GAPDH ratios are shown. (b) Both
cells were transfected with a versican promoter luciferase reporter construct
containing the versican promoter region (559 to þ 353) and part of exon 1
fused to the luciferase gene. Luciferase activity was measured in quadruplicate
and was calculated by setting the luciferase activity of one Fb cell line at
100%. Shown are the mean luciferase activities±SD. (c) The antibody 2B1
specifically bound to versican (around 450 kDa). Dot-blot analysis of versican
protein in conditioned medium.
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cartilage could be successfully reconstructed using a collagen
sponge as a scaffold for chondroprogenitor cells (Togo et al.,
2006). Accordingly, these sponges, which consist of chemi-
cally cross-linked collagen resistant to collagenase digestion
in vivo, were used in our ex vivo model. Collagen sponges
were seeded with 5105 KL cells (KL-SPos) or Fbs (Fb-SPos)
and then implanted into the subcutaneous space of nude
mice (Figure 4a). After various incubation periods, the KL-SPo
and Fb-SPo were removed and weighed. After 1 month, the
KL-SPos were less translucent (Figure 4a) and were signifi-
cantly heavier than the Fb-SPos (29±8.1mg vs 17±6.9mg,
respectively; Figure 4a). In contrast, a 3D in vitro incubation
of KL-SPos and Fb-SPos for 1 month did not result in
significant weight differences (Figure 4b). In sponges incu-
bated subcutaneously for 1 month, hematoxylin–eosin and
alcian blue staining, respectively, showed that greater
amounts of ground substances and GAGs had been deposited
in the KL-SPos than in the Fb-SPos (Figure 4c). Immunostain-
ing evidenced larger amounts of versican, but not of
hyaluronan (data not shown), in the KL-SPos than in the Fb-
SPos (Figure 4d).
Injections with chondroitinase ABC or IL-1b reduced implant
growth
The implants were treated with chondroitinase ABC to deter-
mine whether the weight increase in the KL-SPo could be
suppressed by removing the CS/DS chains of PGs, including
versican. Weekly injections of 0.5U of chondroitinase ABC
for 1 month caused a significant reduction in the weight of
KL-SPo (from 26±6.7mg to 14±6.8mg; Figure 5a). In the
KL-SPos, alcian blue staining revealed that the chondroitinase
ABC injections had substantially reduced GAG deposition
(Figure 5b), whereas versican immunostaining demonstrated
that the enzymatic removal of the CS/DS chains caused a
significant decrease in the levels of the core proteins of the
PGs (Figure 5b). These data suggest that versican deposition
in the KL-SPos is mediated by CS/DS–chain interactions with
other matrix components. In contrast, the amount of collagen
deposition in the injected KL-SPos and uninjected KL-SPos
was essentially the same, as shown by Masson trichrome
staining (Figure 5b).
As exogenous IL-1b reduced versican expression in vitro,
we tested its effect on KL-SPos. Although there were no
significant differences in alcian blue staining, Masson
trichrome staining, and versican immunostaining between
IL-1b-treated and nontreated sponges (data not shown), a
significant reduction of weight was achieved with three-
times-weekly injections of the cytokine (Figure 5c).
DISCUSSION
Although it is clear that normal wound-healing processes are
derailed in individuals predisposed to developing keloids, the
pathogenic mechanisms of keloids are poorly understood,
including those resulting in excess ECM production (Wolfram
et al., 2009). PGs are expressed in large amounts in keloids
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Figure 3. Analysis of signaling pathways and the effects of IL-1b on versican expression in vitro. (a) In keloid lesion (KL) cells (closed column) and fibroblasts
(Fbs) (blank column), PI3K was blocked by the addition of LY294002 (LY), p38 MAPK by SB202190 (SB), and ERK by PD98059 (PD). *Po0.001. (b) KL cells
or Fbs were treated with IL-1b. (c) Transfection was carried out 48 hours before stimulation of the cells with IL-1b (20Uml1). (d) Both cell types were
treated with recombinant IL-1 receptor antagonist and/or IL-1b. Versican/glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ratios or luciferase promoter
activity was calculated by setting the value obtained from the untreated KL cells or Fb at 100%. All experiments were performed in triplicate. Representative
data, expressed as the mean±SD, are shown.
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and, because of their GAG-mediated capacity to retain large
amounts of water, are likely to have important roles in
determining the volume of these aberrant tissues. We pre-
viously reported that the GAGs deposited in keloid tissues
mainly consist of CS/DS (Ikeda et al., 2009). Of the three PGs
showing increased expression in keloids, lumican GAGs only
carry keratan sulfate chains. Because the major GAG found in
keloids is CS (Ikeda et al., 2009), we ruled out lumican as one
of the PGs whose level is increased in keloids. In our earlier
study of keloids, we were unable to detect aggrecan expres-
sion by northern blotting; thus, we assumed its expressions to
be weak in keloid tissue (Naitoh et al., 2005). Therefore, we
focused on versican as the major PG deposited in keloids.
Several groups have attempted to generate animal models
of keloids (e.g., by implanting a piece of human keloid tissue
into mice (Waki et al., 1991; Polo et al., 1998)); however, to
date, they have not been widely used (Ramos et al., 2008).
Recently, hypertrophic scar tissue implanted into nude mice
was shown to undergo a significant size reduction in response
to the direct application of basic Fb growth factor (Eto et al.,
2012). However, we preliminarily tried to implant small
pieces of keloid tissue into nude mice, but after 1 month,
these pieces had undergone various degrees of size reduc-
tion, probably due to matrix degradation. It may be that size
is a critical factor in the prolonged maintenance of the
implanted tissue, which is influenced by the proper distribu-
tion of nutrients and/or oxygen from the surrounding tissue.
In an earlier study, we succeeded in obtaining cartilage
production in the subcutaneous space of nude mice by using
a chemically cross-linked collagen sponge seeded with
chondroprogenitor cells (Togo et al., 2006). Accordingly,
we speculated that these sponges would be an excellent
material for studying the mechanisms of GAG deposition in
keloids. Indeed, after 1 month, the KL-SPos were heavier than
the Fb-SPos. This result in turn implied that the efficacy of test
compounds in suppressing keloid volume could be estimated
simply by weighing the sponges. Another advantage of the
collagen sponges is that their elasticity facilitates injection
with the various candidate therapeutic compounds. A
sponge-like scaffold fabricated from polylactic acid (Chung
et al., 2008) was also tested, but it did not result in significant
versican deposition (data not shown).
One of the aims of this study was to identify compounds
that inhibited the growth of the KL-SPos. As TGF-b stimulates
versican expression in dermal Fbs under in vitro conditions
(Kahari et al., 1991), blockade of the TGF-b signaling
pathway may also be a potent candidate keloid-treatment
modality. Similarly, it would be interesting to examine the
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effects of PI3K and p38MAPK inhibitors on GAG deposition
in our ex vivo system. Downregulation of versican deposition
by IL-1b was observed in KL cells in our ex vivo model. Thus,
IL-1b may be of therapeutic interest in keloids. Chondroiti-
nase ABC may also be a potent inhibitor of keloid formation
based on its ability to remove GAGs, as demonstrated in
our ex vivo model. A reduction in keloid volume would be
sufficient to relieve many of the clinical symptoms and
cosmetic problems of affected individuals. Chondroitinase
ABC is currently being tested in a phase III clinical trial in
the USA and Japan for the treatment of interdisc herniation
(http://www.seikagaku.co.jp/english/pdf/76.pdf). The results
of that trial may be applicable to the treatment of keloids.
Although there are currently several treatment modalities
for keloids, many are unsatisfactory because they fail to
prevent recurrence (Butler et al., 2008). We developed a
simple, reliable ex vivo model of keloids that can be used
not only to evaluate novel anti-keloid agents but also to
identify the mechanisms underlying the pathogenesis of
keloids.
MATERIALS AND METHODS
Keloid samples and primary culture
Keloids are defined as raised, red, and inflexible scar tissue that
invades the boundaries of the original wound (Butler et al., 2008).
Keloids and unaffected normal skin tissue specimens were obtained
surgically with written informed consent, with adherence to the
Declaration of Helsinki protocols, and with the approval of the Ethical
Committee of the Kyoto University Medical School. Tissue samples
were taken from keloids located on the shoulder, chest, or abdomen
of six individuals (K1–K6, male:female ratio¼ 4:2; mean age¼ 36.3)
and from normal skin tissue remaining after the surgical removal of
benign tumors located on the face, buttock, abdomen, or inguinal
region of five individuals (N1–N5, male:female ratio¼ 1:4; mean
age¼ 31.6). All of the samples were subjected to histological exa-
mination and mRNA extraction.
Primary cultured cells were obtained from keloids located on the
face, shoulder, chest, back, or abdomen of another eight individuals
(male:female ratio¼ 6:2; mean age¼ 29.4) and from the normal
skin of the face, forearm, buttock, or abdomen of eight additional
individuals (male:female ratio¼ 5:3; mean age¼ 31.4). Primary cell
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culture involved plating small pieces of excised keloid tissue on
plastic dishes in 10% fetal bovine serum/DMEM with antibiotics and
incubating the cultures at 37 1C until the cells grew out of the tissue
pieces. These cells were maintained in the same culture medium and
passaged by a 1:2–3 split when they reached early confluence.
For the signal inhibition assay, KL cells and Fbs were cultured in
medium containing 30 mM LY294002 (PI3K inhibitor), 30 mM
SB202190 (p38 MAPK inhibitor), or 20 mM PD98059 (ERK inhibitor;
all from Calbiochem, Damstadt, Germany). For IL-1b signaling
studies, the cells were cultured in the presence of IL-1b (20Uml1;
Roche Diagnostics, Indianapolis, IN). RNA was purified 15 hours
after IL-1b treatment. Recombinant IL-1 receptor antagonist
(0.5 mgml1; R&D systems, Minneapolis, MN) was applied to both
the KL cells and the Fbs 24 hours before RNA purification.
Animals and operations
The number of animals used in this study was kept to a minimum,
and all possible efforts were made to reduce their suffering, in
compliance with the protocols established by the Animal Research
Committee of Kyoto University.
Immunohistochemistry
For versican immunostaining, mouse anti-human versican mono-
clonal antibody (2B1; from Seikagaku Kogyo, Tokyo, Japan) and
Cy3-conjugated anti-mouse IgGs (Millipore-Chemicon, Billerica,
MA) were used according to the manufacturer’s instructions. For
hyaluronan immunostaining, biotinylated hyaluronic acid–binding
protein (Seikagaku Kogyo) and streptavidin-Cy3 (Sigma-Aldrich,
St Louis, MO) were used according to the manufacturer’s instruc-
tions. Fluorescence immunostaining was analyzed by confocal laser
scanning microscopy using a Zeiss LSM 510 system (Carl Zeiss
Microscopy, Go¨ttingen, Germany).
RT-PCR
Total RNA was extracted and cDNA was synthesized as previously
reported (Ikeda et al., 2009). RT-PCR products were analyzed by
quantitative RT-PCR by using TaqMan probe (Roche Applied
Science, Mannheim, Germany), TaqMan Universal PCR Master
Mix (Applied Biosystems, Carlsbad, CA), and the respective primers
(Sigma-Aldrich) according to the manufacturer’s instructions. Tripli-
cate reactions were performed in an AB7300 real-time thermocycler
(Applied Biosystems) under the following thermal cycles: 2minutes
at 50 1C, 1minute at 95 1C, and 40 cycles of 15 seconds at 95 1C and
1minute at 60 1C. The TaqMan probe and primers used were as
follows: glyceraldehyde 3-phosphate dehydrogenase, probe no. 60,
forward primer, (83–101 nt Genbank NM_002046.3) 50-AGCCA
CATCGCTCAGACAC-30 and reverse primer (130–148 nt) 50-GCCC
AATACGACCAAATCC-30; versican, probe no. 54, forward primer
(9,657–9,675 nt Genbank NM_004385.3) 50-GCACCTGTGTGCC
AGGATA-30 and reverse primer (9,703–9,726 nt) 50-CAGGGATTA
GAGTGACATTCATCA-30; and IL-1 receptor, probe no. 60, forward
primer (1,350–1,371 nt Genbank NM_000877.2) 50-TGTTCATTTAT
GGAAGGGATGA-30 and reverse primer (1,403–1,427 nt) 50-TTCTG
CTTTTCTTTACGTTTTCATT-30.
Transfection and luciferase assays
The promoter activity of KL cells and Fbs was assessed by inserting a
559 to þ 353 region of the human versican gene (GenBank
U15963) (Naso et al., 1994) upstream of the luciferase gene in the
pTAL-luc plasmid (BD Biosciences Clontech, Palo Alto, CA). The
construct was verified by DNA sequencing. KL cells or Fbs were
seeded on 24-well plates at 1.5 105 cells per well and transfected
with Fugene HD (Roche Applied Science) and their luciferase
activities were measured with a Promega Dual Luciferase Reporter
Assay kit (Promega, Madison, WI) according to the manufacturer’s
protocols.
Western and dot-blot analyses of versican protein
To collect conditioned medium, 2.0 105 KL cells or Fbs were
seeded on six-well plates. Two days after serum starvation induced
by culture in 2ml of DMEM, conditioned medium was collected and
used for western blot and dot-blot analyses, which were performed
as described previously (Isogai et al., 1996; Koyama et al., 2007).
Intensities of dots were calculated using ImageQuant TL (GE
Healthcare, Amersham Place, UK). The values were expressed as
the ratios to cell numbers.
Generation of an ex vivo GAG deposition model
Collagen sponges were prepared and were implanted into sub-
cutaneous pockets of nude mice as previously reported (Togo et al.,
2006). Before implanting sponges, they were incubated overnight in
10% fetal bovine serum/DMEM with 5 105 KL cells or Fbs, thus
generating KL-SPo and Fb-SPo, respectively. Four weeks after
implantation, the KL-SPo and Fb-SPo were removed, weighed, and
subjected to histological analysis as follows: after fixation with 10%
phosphate-buffered formalin for 24 hours at 4 1C, the sponges were
embedded in paraffin and sliced into 7.0-mm sections, which were
either stained with hematoxylin–eosin or alcian blue (pH 2.5) or
subjected to immunohistochemical analysis.
Injection of the collagen sponges with chondroitinase ABC and
IL-1b
KL-SPos were injected once a week, starting 1 week post implan-
tation, with Proteus vulgaris chondroitinase ABC (protease free:
0.1U in 50 ml of 0.1% BSA/H2O) or IL-1b (40U in 20 ml of 0.1%
BSA/phosphate-buffered saline). An equal amount of vehicle served
as the control. At 4 weeks post implantation, the mice were killed
and the sponges were removed and analyzed.
cDNA microarray analysis
Total RNA was isolated from cultured KL cells and Fbs using an
RNeasy mini kit (Qiagen, Valencia, CA). Total RNA (1mg) was
amplified and labeled using the One-Cycle Target Labeling kit
(Affymetrix, Santa Clara, CA).
Biotin-labeled cRNA (15 mg) was fragmented and hybridized to
the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix).
The array was incubated and signals were scanned according to the
manufacturer’s protocol. Expression profiles were analyzed based on
the MAS5 algorithm using the GeneChip operating software
(Affymetrix), with further analysis using GeneSpring 7.3 (Agilent
Technologies, Palo Alto, CA). Raw intensity values from each chip
were normalized to the 50th percentile of the measurements. Each
gene was normalized to the median of that gene in the respective
controls to enable the comparison of relative changes in gene
expression levels between different conditions.
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Statistical analysis
Student’s t-test was used to examine differences between experi-
mental groups. The data are expressed as the means±SD. The
calculated P-values were two-sided; Po0.05 was considered
statistically significant.
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